Revolution Medicines (RVMD) Stock Price, News & Analysis

Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Key Stats

• Today's Range: $53.69 to $55.95
• 50-Day Range: $41.63 to $60.60
• 52-Week Range: $20.51 to $62.40
• Volume: 1.26 million shs
• Average Volume: 1.34 million shs
• Market Capitalization: $9.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $61.00
• Consensus Rating: Buy

Revolution Medicines Stock Analysis - MarketRank™

Revolution Medicines scored higher than 71% of companies evaluated by MarketBeat, and ranked 327th out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Revolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Revolution Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Revolution Medicines are expected to decrease in the coming year, from ($3.51) to ($4.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revolution Medicines is -15.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revolution Medicines is -15.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Revolution Medicines has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.78% of the outstanding shares of Revolution Medicines have been sold short.

Short Interest Ratio / Days to Cover

Revolution Medicines has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Revolution Medicines has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Revolution Medicines does not currently pay a dividend.

Dividend Growth

Revolution Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.81

Percentage of Shares Shorted

10.78% of the outstanding shares of Revolution Medicines have been sold short.

Short Interest Ratio / Days to Cover

Revolution Medicines has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Revolution Medicines has recently increased by 8.88%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.01

News Sentiment

Revolution Medicines has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Revolution Medicines this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for RVMD on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,355,624.00 in company stock.

Percentage Held by Insiders

Only 8.00% of the stock of Revolution Medicines is held by insiders.

Percentage Held by Institutions

94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RVMD Stock Analysis - Frequently Asked Questions

How have RVMD shares performed this year?

Revolution Medicines' stock was trading at $28.68 at the beginning of 2024. Since then, RVMD shares have increased by 89.1% and is now trading at $54.24.
View the best growth stocks for 2024 here.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.94) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.05.

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' top institutional shareholders include Wellington Management Group LLP (6.78%), Janus Henderson Group PLC (3.65%), FMR LLC (3.49%) and State Street Corp (3.14%). Insiders that own company stock include Rock Ventures Iii LP Third, Thilo Schroeder, Mark A Goldsmith, Stephen Michael Kelsey, Margaret A Horn, Jack Anders, Lorence H Kim, Jeff Cislini, Xiaolin Wang, Sushil Patel and Barbara Weber.
View institutional ownership trends.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/18/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RVMD
• CUSIP: N/A
• CIK: 1628171
• Web: www.revmed.com
• Phone: 650-481-6801
• Fax: N/A
• Employees: 443
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $61.00
• High Stock Price Target: $82.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +10.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-436,370,000.00
• Net Margins: N/A
• Pretax Margin: -76,377.09%
• Return on Equity: -33.67%
• Return on Assets: -30.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.24
• Quick Ratio: 14.24

Sales & Book Value

• Annual Sales: $11.58 million
• Price / Sales: 801.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.31 per share
• Price / Book: 5.92

Miscellaneous

• Outstanding Shares: 168,220,000
• Free Float: 154,761,000
• Market Cap: $9.28 billion
• Optionable: Optionable
• Beta: 1.40